Research into the disease-modifying effects of the novel cathepsin K inhibitor MIV-711 suggests it may be effective as a knee OA treatment. In OA patients using the treatment, the study documented statistically significant reductions in bone and cartilage progression…
![](https://www.the-rheumatologist.org/wp-content/uploads/2017/05/shutterstock_blueknee_500x270_v2-150x150.jpg)